Zydus Lifesciences Limited Press Release Sep 21 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its oncology injectable manufacturing facility in Ahmedabad. The report indicates that the facility's classification has improved from Official Action Indicated to Voluntary Action Indicated following a recent inspection. This disclosure is made in accordance with regulatory requirements to inform investors and exchange members.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 15 2025
- Press Release Sep 05 2025
- Press Release Sep 04 2025
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
- Press Release Sep 02 2025
Later from Zydus Lifesciences
- Press Release Sep 23 2025
- Press Release Oct 01 2025
- Press Release Oct 06 2025
- Press Release Oct 24 2025
- Press Release Oct 29 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences